Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Issues Earnings Results

Posted by Stacy Sanders on Nov 14th, 2024

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.10), Zacks reports. The company had revenue of $10.96 billion during the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.46%. Bayer Aktiengesellschaft updated its FY 2024 guidance to 5.610-6.045 EPS.

Bayer Aktiengesellschaft Price Performance

Shares of OTCMKTS BAYRY traded down $0.22 during mid-day trading on Thursday, reaching $5.36. The company had a trading volume of 3,506,472 shares, compared to its average volume of 1,362,203. Bayer Aktiengesellschaft has a one year low of $5.33 and a one year high of $11.33. The business’s 50-day simple moving average is $7.39 and its 200 day simple moving average is $7.42. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.27. The firm has a market cap of $21.06 billion, a price-to-earnings ratio of -20.62 and a beta of 1.10.

Analyst Upgrades and Downgrades

Separately, Bank of America raised Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a report on Friday, September 6th. One investment analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Check Out Our Latest Research Report on Bayer Aktiengesellschaft

Bayer Aktiengesellschaft Company Profile

(Get Free Report)

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.